Prognostic Biomarkers and Immunotherapeutic Insights of Circulating Tumor DNA Analysis in Advanced Esophageal Squamous Cell Carcinoma From SCRUM-MONSTAR GOZILA Substudy - PubMed
4 hours ago
- #esophageal cancer
- #circulating tumor DNA
- #immunotherapy
- Genomic profiling of advanced esophageal squamous cell carcinoma (ESCC) identified TP53 as the most common alteration (88.5%), followed by mutations or amplifications in genes like PIK3CA, NFE2L2, CCND1, and EGFR.
- Alterations in NFE2L2, FGFR1, RB1, EGFR, and PIK3CA were linked to worse overall survival, with some being independent poor prognostic factors for patient outcomes.
- Blood tumor mutation burden (bTMB) did not reliably predict the effectiveness of PD-1 inhibitors, showing no significant differences in response rates or progression-free survival across various cutoff values.